Pfizer says it is looking at biotechs as well as other drugmakers as part of a $17 billion budget to buy some of the next billion-dollar drugs over the next two years. The firm plans to get access to the drugs through acquisitions or product licenses, focusing on deals that cost between $1 billion and $4 billion, according to the firm's global research president.

Full Story:
Detroit Free Press

Related Summaries